RegulationFast Track (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), Priority Review (CN), Breakthrough Therapy (CN), Special Review Project (CN), Conditional marketing approval (CN)

Structure/Sequence

Molecular FormulaC23H29ClN8O4

InChIKeyCLMVIXVYZUJPOI-UHFFFAOYSA-N

CAS Registry1402152-13-9

Clinical Trials associated with Copanlisib dihydrochloride

NCT05687721

/ Not yet recruitingPhase 1/2IIT

A Phase II Trial With Copanlisib Plus Avelumab as a Maintenance Therapy for Metastatic Bladder Cancer After Platinum-based Chemotherapy

Patients with metastatic bladder cancer are usually treated with chemotherapy. If their cancers do not progress after chemotherapy, they can be enrolled into this study and receive a standard-of-care immunotherapy medication named avelumab plus a study drug named copanlisib.

Start Date02 Jun 2025

Sponsor / Collaborator

VA Office of Research and Development

[+1]

NCT06218667

/ WithdrawnPhase 1/2IIT

CHARIOT: a Phase 1b/2 Study of Androgen Deprivation Therapy and Copanlisib in High-Risk Localized Prostate Cancer Patients Prior to Radical Prostatectomy

The researchers are doing this study to find out whether copanlisib in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects for people who have localized high-risk prostate cancer.

Start Date11 Jan 2024

Sponsor / Collaborator

Memorial Sloan Kettering Cancer Center

NCT05082025

/ Active, not recruitingPhase 2IIT

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

The purpose of this study is to evaluate the efficacy and safety of copanlisib in combination with fulvestrant in advanced hormone receptor-positive (HR+) solid tumors harboring alterations that activate the Phosphatidylinositol-3 kinase (PI3K) pathway.

Start Date27 Sep 2022

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

100 Clinical Results associated with Copanlisib dihydrochloride

100 Translational Medicine associated with Copanlisib dihydrochloride

100 Patents (Medical) associated with Copanlisib dihydrochloride

329

Literatures (Medical) associated with Copanlisib dihydrochloride

24 Mar 2025·Journal of biomolecular structure & dynamics

Inhibition of respiratory syncytial virus by Daclatasvir and its derivatives: synthesis of computational derivatives as a new drug development

Article

Author: Abdalla, Mohnad ; Mitra, Debanjan ; Afreen, Shagufta ; Das Mohapatra, Pradeep K.

The most common cause of respiratory tract illness in newborns and young children is the respiratory syncytial virus (RSV). There is no approved vaccination or specific antiviral medication for RSV infections. Here, an attempt has been made to explore the potential of currently marketed drugs as well as their probable derivatives to improve the possibility of developing stronger medications against RSV. From the 100 synthetic drug compounds library, the best drug molecule was identified through drug-likeness properties, toxicity, molecular docking and molecular dynamics simulations. Molecular Mechanics Generalized Born Surface Area (MM-GBSA) was also a method that was applied in this study. Daclatasvir showed the highest binding energy and appeared as the best drug to inhibit matrix protein and a fusion protein of RSV. Based on Daclatasvir, 40 computational derivatives were made. D28, D34 and D40 showed far better results than the actual drug. Changes in lipophilicity character increase the binding energy of derivatives. Molecular dynamic simulations showed their non-deviated, non-fluctuated and stable complex formation with target proteins. The high number of amino acid contacts throughout the trajectory increases the stability and effectiveness of derivatives. The key to producing a novel medicine to eradicate RSV is provided by derivatives. Daclatasvir will be employed as a potential RSV inhibitor up until that point.Communicated by Ramaswamy H. Sarma.

01 Jan 2025·Rare Tumors

Durable disease regression with copanlisib treatment in PI3K-mutated metastasizing ameloblastoma: A case report

Article

Author: Knott, Hannah ; Agulnik, Mark ; Pollack, Seth M ; Lynch, Meghan M ; Stencel, Sean ; Obeidin, Farres ; Damodaran, Senthil ; Abbinanti, Susan ; Al-Maryati, Rusul ; Alexiev, Borislav A ; Hermida-Viveiros, Pedro

Ameloblastoma is a rare tumor arising from odontogenic cells that is benign, yet locally aggressive. Metastasizing ameloblastoma (METAM) is an ultra-rare ameloblastoma variant in which both primary and secondary tumors have histological features of benign ameloblastoma. This is a case report of a patient who presented with a jaw mass and subsequent lung metastases, later diagnosed as METAM. Initial treatments, including carboplatin, etoposide, and taxane-based chemotherapy, were ineffective. Molecular profiling revealed mutations including PIK3CA H1047R and BRAF V600E. The patient was enrolled in a tumor-agnostic trial and began treatment with copanlisib, a PI3K inhibitor, which resulted in a partial response and durable disease regression. After 76 cycles, she continues to tolerate therapy well with minimal adverse events. This case highlights the potential of targeted therapies such as copanlisib for treating METAM, providing a promising therapeutic option for patients with PIK3CA mutations.

04 Dec 2024·JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY

Characterization of Anticancer Drug Protomers Using Electrospray Ionization and Ion Mobility Spectrometry–Mass Spectrometry

Article

Author: Riedel, Jerome ; Volmer, Dietrich A. ; Safferthal, Marc ; Kovacevic, Borislav ; Schorr, Pascal ; Basuri, Pallab ; Pagel, Kevin

We used electrospray ionization and ion mobility spectrometry-mass spectrometry to detect and characterize the three anticancer drugs palbociclib, copanlisib, and olaparib. Ion mobility-mass spectrometry and density functional theory revealed that these compounds generate isomers during ionization (protomers) due to the presence of multiple protonation sites within their chemical structures. Our work has implications for understanding the solution- and gas-phase chemistry of these molecules during spray-based ionization processes.

News (Medical) associated with Copanlisib dihydrochloride

23 Feb 2025

·synapse.patsnap.com

Progress in the Research and Development of PI3Kα Drug Targets

PI3Kα is a crucial lipid kinase and one of the most frequently mutated kinases in cancer. It consists of a heterodimer composed of the catalytic subunit p110α and the regulatory subunit p85α. It is closely associated with cell growth and proliferation, and its acquired functional mutations serve as driving factors in tumor formation, making it a significant target for cancer treatment. In the field of PI3Kα targeted drug development, data from the Synapse database shows that there are currently 60 drugs being developed that target PI3Kα. These drugs cover 88 indications, with 85 development organizations actively participating in research and competition in this field, highlighting its importance in pharmaceutical research. Additionally, 462 clinical trial results, 4240 patents, and 8139 literature have further strengthened the feasibility and research progress of PI3Kα-targeted drugs. These data reflect the level of activity in the field of PI3Kα-targeted drugs and its future development potential. Competition Landscape of PI3Kα In the R&D of PI3Kα targeted drugs, large pharmaceutical companies such as Novartis, Bayer, and Roche are actively participating. Novartis and Bayer have been successful in launching Alpelisib and Copanlisib respectively, demonstrating high market competitiveness. The active participation of these companies has intensified the competition in PI3Kα targeted drugs sector, offering hopes for more treatment options for patients. The development of PI3Kα-targeted drugs for various indications has made positive progress, generating widespread attention. In the field of breast cancer, 19 drugs are currently under development, demonstrating the potential and research investment in this area. These data reflect the broad application prospects of PI3Kα-targeted drugs in multiple tumor types, while also highlighting the enthusiasm and efforts of different research institutions in developing drugs for specific indications. With further research and the conduct of clinical trials, it is expected that more PI3Kα-targeted drugs will be introduced, bringing new breakthroughs and hopes for the treatment of these diseases. Key Drug Alpelisib, developed by Novartis, is an orally available small molecule alpha-specific PI3K inhibitor. On May 24, 2019, the U.S. FDA approved the combined use of alpelisib and the endocrine therapy fulvestrant for the treatment of patients with HR+/HER2- advanced or metastatic breast cancer carrying PIK3CA gene mutations. This is the first PI3K inhibitor approved by the FDA for the treatment of breast cancer, and also the first New Molecular Entity (NME) approved under the FDA's Real-Time Oncology Review (RTOR) pilot program. This approval validates the safety and efficacy of Piqray in clinical practice. RLY-2608 is known as the first pan-allosteric variant (H1047X, E542X, and E545X), and as an allosteric selective PI3Kα inhibitor designed to overcome these limitations. RLY-2608 is currently under clinical trial, aiming to treat patients with advanced solid tumors carrying PIK3CA (PI3Kα) mutations. Based on the preclinical data of RLY-2608, the KD calculations evaluated by Surface Plasmon Resonance (SPR) demonstrate that RLY-2608 preferentially binds to mutated proteins, compared to Alpelisib. Moreover, buparlisib, an orthosteric site inhibitor, cannot eliminate this binding, proving that RLY-2608 has generated a new binding site. RLY-2608 binds to the mutated proteins more quickly. RLY-2608 has superior biochemical selectivity for mutant PI3Kα than WT and other family subtypes. RLY-2608 has extremely high kinase selectivity, reducing the possibility of off-target side effects. RLY-2608 inhibits phosphorylated AKT (pAKT) in PIK3CA mutant cancer cell lines, regardless of hotspot mutations. After extended incubation (5 days), RLY-2608 can inhibit proliferation. RLY-2608 displays effective tumor growth inhibition in a dose-dependent manner, and can achieve complete regression at doses with smaller impact on insulin levels, compared to positive control inhibitors. However, at equivalent doses, RLY-2608 does not demonstrate better tumor growth inhibition (compared to GDC-077 and Alpelisib). This could be because other PI3K isoforms such as δ can act as anti-tumor agents via immune regulation. As a single PI3Kα inhibitor, RLY-2608 theoretically sacrifices potency to enhance safety. In other disclosed data, RLY-2608 achieved maximum therapeutic effects in both kinase and helical structural domain PIK3CA mutated heterologous transplantation models, significantly reducing the rise in insulin levels compared to conformational inhibitors. Across different species, the exposure of RLY-2608 dosage exceeded the mutated PI3Kα cell PD IC90, without causing an increase in glucose levels or histopathological changes associated with glucose metabolism disorders. These pre-clinical results support the clinical study of RLY-2608 as a mutated PI3Kα inhibitor. Currently, RLY-2608 is under investigation in a Phase 1 clinical trial. This is an open-label First-in-Human (FIH) study aimed at evaluating the Maximum Tolerated Dose (MTD), safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and preliminary anti-tumor activity of RLY-2608 in patients with late-stage solid tumors harboring PIK3CA mutations in blood and/or tumor. There is an increasing breakthrough in clinical trials of PI3Kα inhibitors, but the high toxicity and other side effects brought by PI3Kα inhibitors also pose a significant challenge for clinical application. Traditionally, the development of PI3Kα inhibitors has primarily focused on the active site or allosteric site. Therapeutic indications of allosteric inhibitors are limited by the lack of clinically meaningful mutant and wild type (WT) PI3Kα selectivity and pan-isomeric activity. More progress in drug clinical trials is expected to bring blessings to patients. The content above comes from the network. if any infringement, please contact us to modify.

09 Aug 2024

·www.fda.gov

FDA grants accelerated approval to copanlisib for relapsed follicular lymphoma

On September 14, 2017, the U.S. Food and Drug Administration granted accelerated approval to copanlisib (ALIQOPA, Bayer HealthCare Pharmaceuticals Inc.) for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. Approval was based on efficacy results in 104 patients with relapsed follicular lymphoma enrolled in an open-label, single-arm, multicenter, phase 2 trial. Patients received 0.8 mg/kg or 60 mg of copanlisib by intravenous infusion on days 1, 8, and 15 of a 28-day treatment cycle. The objective response rate was 58.7% (95% CI: 48.6%-68.2%) with an estimated median response duration of 12.2 months (range, 0+ to 22.6 months). The complete response rate was 14.4% and partial response rate was 44.2%. The safety population included 168 patients with follicular lymphoma and other hematologic malignancies treated with the recommended copanlisib dosing regimen. Common adverse reactions in greater than 20% of patients include hyperglycemia, diarrhea, fatigue, hypertension, leukopenia, neutropenia, nausea, lower respiratory tract infections, and thrombocytopenia. The most common grade 3-4 adverse reactions include hyperglycemia, leukopenia, hypertension, neutropenia, and lower respiratory tract infections. Serious non-infectious pneumonitis occurred in 6% of patients. The recommended copanlisib dose is 60 mg administered as a 1-hour intravenous infusion on days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (three weeks on and one week off). Full dosing information is available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209936s000lbl.pdf FDA previously granted orphan drug and fast track designation for copanlisib. As a condition of accelerated approval, a randomized controlled trial will be required to verify the clinical benefit of copanlisib. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics, available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301.pdf. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System by completing a form online at http://www.fda.gov/medwatch/report.htm, by faxing (1-800-FDA-0178) or mailing the postage-paid address form provided online, or by telephone (1-800-FDA-1088). Follow the Oncology Center of Excellence on Twitter@FDAOncology. Check out recent approvals at the OCE’s new podcast, Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.), available at www.fda.gov/DISCO. Content current as of: 09/14/2017 09/14/2017 Resources for Information | Approved Drugs Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) Short Description Oncology (Cancer)/Hematologic Malignancies Approval Notifications Ongoing | Cancer Accelerated Approvals Verified Clinical Benefit | Cancer Accelerated Approvals Withdrawn | Cancer Accelerated Approvals Other | Cancer Accelerated Approvals Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) Short Description

Accelerated ApprovalClinical ResultFast TrackDrug ApprovalOrphan Drug

08 Aug 2024

·www.echemi.com

Regulatory Challenges of Gene Therapy and Cancer Drugs: Industry Trends Behind the Withdrawal of Zydelig and FDA's Response

In 2022, Gilead announced that it would voluntarily withdraw Zydelig from the U.S. market for two lymphoma treatments, a full six years after it suspended the trial due to patient deaths. A Gilead spokesperson clarified that the withdrawal was not due to safety concerns, but rather because of insurmountable obstacles to recruiting subjects for additional research trials required by the FDA. Nevertheless, Zydelig retains its eligibility for the treatment of chronic lymphocytic leukemia and remains on the market for patients. Notably, the withdrawal of Zydelig coincides with the withdrawal of several other PI3K inhibitors used to treat follicular lymphoma: Secura Bio's duvelisib (trade name Copiktra) withdrawn in December 2021, TG's umbralisib (trade name Ukoniq) withdrawn in 2022 (here may be a clerical error, read "February" or adjusted to another month), Bayer's copanlisib (trade name Aliqopa) also withdrew from the market in November 2023. Together, these events outline an industry trend. A study published in JAMA Internal Medicine reveals an interesting data point: Before Gilead decided to withdraw some uses of Zydelig from the U.S. market, its global sales had reached a staggering $842 million. This reflects the wide application and high recognition of the drug in the market, although it ultimately failed to fully meet all expectations for various reasons. Interestingly, the pharmaceutical industry sometimes employs a series of ingenious strategies to speed up the process of bringing a product to market. Eli Lilly, for example, successfully used all four avenues of acceleration to bring oncology product Lartruvo to market in 2016. The key clinical data for the product is based only on the results of a trial involving 133 patients, and while the results showed a possible positive impact on survival outcomes for sarcoma, a cancer that affects muscles and other soft tissues, the specific effect on slowing cancer growth is unclear. However, just over two years later, a larger study revealed that Lartruvo had no significant impact on patient survival, and Eli Lilly had to withdraw it from the market. Despite this, Lartruvo still managed to achieve a whopping $500 million in sales during its short market life. Among the many drugs approved for accelerated marketing, oncology products have become the hardest hit by ineffective drugs. However, as the development of therapies continues to deepen and progress, new questions continue to emerge and are presented to the FDA. In particular, advanced therapies represented by cell and gene therapies, when they meet with the accelerated approval system, have brought unprecedented challenges to this "old revolution". Given the complexity of cell and gene therapies and the relative lack of understanding of their safety, once ineffective advanced therapies are released to the market, the consequences and impacts will be far beyond the scope of small molecule ineffective drugs. For example, the tragic death of a three-year-old boy in a clinical trial of Pfizer's fordadistrogene movaparvovec, a gene therapy for Duchenne muscular dystrophy, highlights the shortcomings and limitations of researchers in predicting the potential for serious adverse events. As vectors of ssRNA (single stranded RNA), viruses (such as AAV) play a critical role in gene therapy, but can also cause a series of serious adverse events including cardiopulmonary failure, myocarditis, thrombotic microangiopathy, and acute liver failure. These potential risks have forced the FDA to be more cautious and rigorous in approving gene therapies. Speaking at the annual meeting of the American Society for Gene and Cell Therapy, CBER director Peter Marks said speeding up the withdrawal of approved gene therapies could be easier and faster than for small-molecule therapies. At the same time, he stressed that "accelerated approval of gene therapy is not a get-out-of-jail-free ticket." The FDA will not hesitate to withdraw accelerated approval of rare disease gene therapies if they fail subsequent confirmatory trials." Marks further points out that the "one-size-fits-all" nature of gene therapy makes confirmatory studies easier to follow and monitor patients over time. It also makes for greater clarity and clarity on the question of whether to withdraw gene therapy. In contrast, there may be more controversy and disagreement in the decision process of withdrawing cancer therapy. Marks, however, said the FDA would only withdraw gene therapy if it was clear that the patient benefit was likely to be "minimal" but the side effects were significant. He cited a case in which Bluebird Bio's sickle cell gene therapy Lyfgenia (lovotibeglogene autotemcel) caused patients to develop myelodysplastic syndrome and leukemia during treatment. The product was approved by the FDA in December 2023 with a boxed warning about hematologic malignancies. Marks said it is unclear whether these malignancies are related to the preconditioning regimen associated with Lyfgenia treatment, the underlying disease, or the gene therapy itself. In addition, the case of drug manufacturers refusing to voluntarily withdraw the market is not unique in the history of FDA accelerated approval. Everything from the withdrawal of Makena, a drug that reduced the risk of preterm birth, after 12 years on the market, to the legal battle between Pepaxto and the FDA highlights the complexity and seriousness of the issue. In the face of these challenges, FDA has to seek the support of legislation to strengthen its regulatory power and capability. Fortunately, the introduction of the FDORA (Comprehensive Food and Drug Reform Act) bill provides the FDA with greater flexibility and autonomy to act without public hearings.

Drug ApprovalGene Therapy

100 Deals associated with Copanlisib dihydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
-	Copanlisib dihydrochloride	L01XX61	DB12483

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Follicular Lymphoma	US	Bayer HealthCare Pharmaceuticals, Inc.	14 Sep 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Indolent B-Cell Non-Hodgkin Lymphoma	NDA/BLA	CA	Bayer, Inc.	01 Dec 2021
Small Lymphocytic Lymphoma	NDA/BLA	CA	Bayer, Inc.	01 Dec 2021
Waldenstrom Macroglobulinemia	NDA/BLA	CA	Bayer, Inc.	01 Dec 2021
Marginal Zone B-Cell Lymphoma	NDA/BLA	EU	Bayer AG	12 Jun 2021
Non-Hodgkin Lymphoma	NDA/BLA	CN	Bayer AG	10 Mar 2021
Indolent Non-Hodgkin Lymphoma	Phase 3	US	Bayer Pharma AG	06 Jan 2016
Indolent Non-Hodgkin Lymphoma	Phase 3	US	Bayer Healthcare Co., Ltd.	06 Jan 2016
Indolent Non-Hodgkin Lymphoma	Phase 3	AR	Bayer Healthcare Co., Ltd.	06 Jan 2016
Indolent Non-Hodgkin Lymphoma	Phase 3	AR	Bayer Pharma AG	06 Jan 2016
Indolent Non-Hodgkin Lymphoma	Phase 3	AU	Bayer Pharma AG	06 Jan 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02626455 (CHRONOS-4, CTgov)	Phase 3	Recurrent Indolent Non-Hodgkin Lymphoma	551	Copa (SRI: Copa+R-B 45 mg)	vaynlllugf(raqwsnezba) = ylujsiinrq boztpjevhq (zywjrddakn, xpbzdrsjrt - fijjcuaghj) View more	-	11 Dec 2024
NCT02626455 (CHRONOS-4, CTgov)	Phase 3	Recurrent Indolent Non-Hodgkin Lymphoma	551	Copa (SRI: Copa+R-B 60 mg (Excluding Subjects From Japan))	vaynlllugf(raqwsnezba) = jkyqbbhvgb boztpjevhq (zywjrddakn, hwhgyibsbw - uobuvzxmqf) View more	-	11 Dec 2024
NCT02626455 (CHRONOS-4, Pubmed \| Blood Adv) Manual	Phase 3	Indolent B-Cell Non-Hodgkin Lymphoma	524	Copanlisib rituximabbendamustine	xmywozluvz(lqdqduidyb) = pywcrmxtuc lltdvegekf (zuwwtrladr, 24.4 - 38.6)	Negative	24 Sep 2024
NCT02626455 (CHRONOS-4, Pubmed \| Blood Adv) Manual	Phase 3	Indolent B-Cell Non-Hodgkin Lymphoma	524	Placebo rituximabbendamustine	xmywozluvz(lqdqduidyb) = ebkqqwncwn lltdvegekf (zuwwtrladr, 27.8 - 42.8)	Negative	24 Sep 2024
NCT04933617 (CTgov)	Phase 1	High grade B-cell lymphoma \| T-cell/histiocyte rich large B-cell lymphoma \| Burkitt Lymphoma	8	copanlisib (All Participants)	xjyxurbain(fwgoyyonzy) = upwqrjvdph ggtqjzwoeg (fwxlgbgbqn, phlvmxzbln - wwevzfmvzn)	-	09 Jul 2024
NCT04933617 (CTgov)	Phase 1		8	Copanlisib (Dose Escalation: Arm 1, Dose Level 1, Original: 30mg Copanlisib)	dlbsowjcla(xkmtrttfav) = eccojtegzv ryaoddwyvf (uttsgnazvr, zakvtmgeqf - dopfrnjxij) View more	-	09 Jul 2024
NCT03484819 (ASH2023)	Phase 2	Mediastinal large B-cell lymphoma \| Diffuse large B-cell lymphoma recurrent	106	Copanlisib	valoilolhu(jlazxksifl) = xjdrggdknk mlgclrqgcy (xztrssmidy, 5 - 57)	-	11 Dec 2023
ASH2023	Phase 2	Follicular Lymphoma	28	Copanlisib 60mg + Rituximab 375mg	trvuhqobeu(eodaiazuaf) = cmwcyloype ctnxzxluvr (wcbefqfzqu ) View more	-	09 Dec 2023
NCT04433182 (FIL Copa-RB, ASH2023)	Phase 2	Diffuse large B-cell lymphoma recurrent	37	Copanlisib + Rituximab + Bendamustine	usjdkuqyxz(dqxwjwxgza) = nqkjzrwqrl xayjgjnctg (thljpracvf, 13.6 - 38.5) View more	-	09 Dec 2023
NCT04572763 (ASH2023)	Phase 1	Diffuse large B-cell lymphoma recurrent	12	Copanlisib	fckvgvvvvd(zdeljxwkai) = kkufyikept ikmtfykbio (kqxtezpakz ) View more	-	09 Dec 2023
ASH2023	Phase 1	Non-Hodgkin Lymphoma \| Richter's syndrome	25	Copanlisib+Nivolumab	yoboplvbrd(htqrswpfyo) = rindzuawsf vxxherndcc (rjmzlixpcr ) View more	-	09 Dec 2023
NCT02369016 (CHRONOS-2, CTgov)	Phase 3	Refractory Indolent Non-Hodgkin Lymphoma	25	Copanlisib (Copanlisib (BAY80-6946, Aliqopa))	qzryoyymxc(iavltibsum) = myxuefiokc pdlivucktg (qatsaishdu, oqlwupivlp - ryezksyyoe) View more	-	18 Nov 2023
NCT02369016 (CHRONOS-2, CTgov)	Phase 3	Refractory Indolent Non-Hodgkin Lymphoma	25	placebo (Placebo)	qzryoyymxc(iavltibsum) = ixhfnuqtuj pdlivucktg (qatsaishdu, wumfgzzyze - zecbgznhux) View more	-	18 Nov 2023
NCT04317105 (NCI10221, ESMO2023)	Phase 2	Advanced Malignant Solid Neoplasm	-	Copanlisib	vrgoytonkf(cfhnrfgczo) = jaqmpfhfdz dqdyjfvzbw (lxomoczobu )	-	23 Oct 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis